These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1035 related articles for article (PubMed ID: 36002891)

  • 1. Plasma apolipoprotein E levels in longitudinally followed patients with mild cognitive impairment and Alzheimer's disease.
    Giannisis A; Al-Grety A; Carlsson H; Patra K; Twohig D; Sando SB; Lauridsen C; Berge G; Grøntvedt GR; Bråthen G; White LR; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2022 Aug; 14(1):115. PubMed ID: 36002891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls.
    Martínez-Morillo E; Hansson O; Atagi Y; Bu G; Minthon L; Diamandis EP; Nielsen HM
    Acta Neuropathol; 2014 May; 127(5):633-43. PubMed ID: 24633805
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasma apolipoprotein E levels, isoform composition, and dimer profile in relation to plasma lipids in racially diverse patients with Alzheimer's disease and mild cognitive impairment.
    Giannisis A; Al-Grety A; Carlsson H; Howell JC; Hu WT; Kultima K; Nielsen HM
    Alzheimers Res Ther; 2023 Jul; 15(1):119. PubMed ID: 37400888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of oxidative stress and inflammatory metabolites with Alzheimer's disease cerebrospinal fluid biomarkers in mild cognitive impairment.
    Ahmad S; Yang W; Orellana A; Frölich L; de Rojas I; Cano A; Boada M; Hernández I; Hausner L; Harms AC; Bakker MHM; Cabrera-Socorro A; Amin N; Ramírez A; Ruiz A; Van Duijn CM; Hankemeier T
    Alzheimers Res Ther; 2024 Jul; 16(1):171. PubMed ID: 39080778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. APOE ε4 is associated with higher levels of CSF SNAP-25 in prodromal Alzheimer's disease.
    Wang S; Zhang J; Pan T;
    Neurosci Lett; 2018 Oct; 685():109-113. PubMed ID: 30144541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of APOE gene with longitudinal changes of CSF amyloid beta and tau levels in Alzheimer's disease: racial differences.
    Xu C; Xiao D; Su BB; Saveron JM; Gamez D; Navia RO; Wang N; Roy U; Adjeroh DA; Wang K;
    Neurol Sci; 2024 Mar; 45(3):1041-1050. PubMed ID: 37759100
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Role of Apolipoprotein E ε4 in Early and Late Mild Cognitive Impairment.
    Luo Y; Tan L; Therriault J; Zhang H; Gao Y;
    Eur Neurol; 2021; 84(6):472-480. PubMed ID: 34340229
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sex differences in CSF biomarkers vary by Alzheimer disease stage and
    Babapour Mofrad R; Tijms BM; Scheltens P; Barkhof F; van der Flier WM; Sikkes SAM; Teunissen CE
    Neurology; 2020 Oct; 95(17):e2378-e2388. PubMed ID: 32788242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
    Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
    Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
    Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
    Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
    Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
    BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
    Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
    Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Aβ42/40 ratio, p-tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross-sectional and longitudinal study in the AIBL cohort.
    Chatterjee P; Pedrini S; Doecke JD; Thota R; Villemagne VL; Doré V; Singh AK; Wang P; Rainey-Smith S; Fowler C; Taddei K; Sohrabi HR; Molloy MP; Ames D; Maruff P; Rowe CC; Masters CL; Martins RN;
    Alzheimers Dement; 2023 Apr; 19(4):1117-1134. PubMed ID: 36574591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interactions between apolipoprotein E, sex, and amyloid-beta on cerebrospinal fluid p-tau levels in the European prevention of Alzheimer's dementia longitudinal cohort study (EPAD LCS).
    Saunders TS; Jenkins N; Blennow K; Ritchie C; Muniz-Terrera G
    EBioMedicine; 2022 Sep; 83():104241. PubMed ID: 36041266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
    Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
    J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
    Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
    Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 52.